Bone Marrow Mesenchymal Stem Cell-Derived Exosomal microRNA-29b-3p Promotes Angiogenesis and Ventricular Remodeling in Rats with Myocardial Infarction by Targeting ADAMTS16

Zheng, Jialin; Zhang, Xinjin; Cai, Wanzhi; Yang, Yongyi; Guo, Tao; Li, Jianmei; Dai, Hualei

doi:10.1007/s12012-022-09745-7

Cited by 18 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, BMSC‐secreted exosomes containing miR‐29b‐3p can improve myocardial angiogenesis and ventricular remodeling in myocardial infarction rats by targeting ADAMTS16, 58 a gene that exacerbates cardiac fibrosis, hypertrophy and heart failure 59 . In another study, exosomes derived from human umbilical cord MSCs treated with macrophage migration inhibitory factor were found to promote cellular proliferation, migration and angiogenesis by transferring mir‐133a‐3p to HUVECs 40 …”

Section: The Role Of Msc‐derived Exosomes In the Treatment Of Myocard...mentioning

confidence: 99%

“…In this case, the proangiogenic effect of mir-210 in exosome treatment is related to its interactions with Efna3, an important gene in angiogenesis. 44 Furthermore, BMSC-secreted exosomes containing miR-29b-3p can improve myocardial angiogenesis and ventricular remodeling in myocardial infarction rats by targeting ADAMTS16, 58 a gene that exacerbates cardiac fibrosis, hypertrophy and heart failure. 59 In T A B L E 1 Mesenchymal stem cell-derived exosomes that promote angiogenesis.…”

Section: Promoting Angiogenesismentioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal stem cell‐derived exosomes in myocardial infarction: Therapeutic potential and application

Li,

Tang,

Yin

et al. 2023

The Journal of Gene Medicine

View full text Add to dashboard Cite

Myocardial infarction refers to the irreversible impairment of cardiac function resulting from the permanent loss of numerous cardiomyocytes and the formation of scar tissue. This condition is caused by acute and persistent inadequate blood supply to the heart's arteries. In the treatment of myocardial infarction, Mesenchymal stem cells (MSCs) play a crucial role because of their powerful therapeutic effects.These effects primarily stem from the paracrine secretion of multiple factors by MSCs, with exosome‐carried microRNAs being the most effective component in promoting cardiac function recovery after infarction. Exosome therapy has emerged as a promising cell‐free treatment for myocardial infarction as a result of its relatively simple composition, low immunogenicity and controlled transplantation dose. Despite these advantages, maintaining the stability of exosomes after transplantation and enhancing their targeting effect remain significant challenges in clinical applications. In recent developments, several approaches have been designed to optimize exosome therapy. These include enhancing exosome retention, improving their ability to target specific effects, pretreating MSC‐derived exosomes and employing transgenic MSC‐derived exosomes. This review primarily focuses on describing the biological characteristics of exosomes, their therapeutic potential and their application in treating myocardial infarction.

show abstract

Section: The Role Of Msc‐derived Exosomes In the Treatment Of Myocard...mentioning

confidence: 99%

Section: Promoting Angiogenesismentioning

confidence: 99%

Mesenchymal stem cell‐derived exosomes in myocardial infarction: Therapeutic potential and application

Li,

Tang,

Yin

et al. 2023

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

“…Emerging evidence has shown that treatments with MSC‐EVs are more successful and exhibit better efficacy than those with MSCs. As reported in various studies, bMSC‐EVs have recently been shown to improve cardiac function, promote neo‐angiogenesis both in vitro and in vivo, improve cardiac indices, reduce infarct size, and regulate homeostasis in various rodent models of myocardial infarction (MI) (Kore et al., 2021, Sun et al., 2020, Yao et al., 2021, Zheng et al., 2022). Additionally, MSC‐EVs have been reported to regulate neuroinflammation, neurogenesis (Izquierdo‐Altarejos et al., 2023), repair ischemic stroke (Davis et al., 2021), and improve neurological function in various animal models of traumatic brain injury (TBI) (Amini et al., 2023), Parkinson's disease (PD), and Alzheimer's disease (AD) (Reed & Escayg, 2021).…”

Section: Types Of Extracellular Vesicles (Evs)mentioning

confidence: 99%

Mesenchymal stem cell‐derived extracellular vesicles: Recent therapeutics and targeted drug delivery advances

Bhat,

Malik,

Yadav

et al. 2024

J of Extracellular Bio

View full text Add to dashboard Cite

The targeted drug delivery field is rapidly advancing, focusing on developing biocompatible nanoparticles that meet rigorous criteria of non‐toxicity, biocompatibility, and efficient release of encapsulated molecules. Conventional synthetic nanoparticles (SNPs) face complications such as elevated immune responses, complex synthesis methods, and toxicity, which restrict their utility in therapeutics and drug delivery. Extracellular vesicles (EVs) have emerged as promising substitutes for SNPs, leveraging their ability to cross biological barriers, biocompatibility, reduced toxicity, and natural origin. Notably, mesenchymal stem cell‐derived EVs (MSC‐EVs) have garnered much curiosity due to their potential in therapeutics and drug delivery. Studies suggest that MSC‐EVs, the central paracrine contributors of MSCs, replicate the therapeutic effects of MSCs. This review explores the characteristics of MSC‐EVs, emphasizing their potential in therapeutics and drug delivery for various diseases, including CRISPR/Cas9 delivery for gene editing. It also delves into the obstacles and challenges of MSC‐EVs in clinical applications and provides insights into strategies to overcome the limitations of biodistribution and target delivery.

show abstract

“…BMSC-derived exosomes can inhibit harmful ventricular remodeling. They contain miR-185, which downregulates suppressor of cytokine signaling 2 (SOCS2), an inhibitor of growth hormone/IGF signaling [ 69 ]; and miR-29b-3p, which downregulates A disintegrin and metalloproteinase with thrombospondin 16 (ADAMTS16), blocking myocardial fibrosis and promoting angiogenesis in a rat model of MI [ 70 ].…”

Section: Other Effectsmentioning

confidence: 99%

Advances in the study of exosomes derived from mesenchymal stem cells and cardiac cells for the treatment of myocardial infarction

Liu

Wang

et al. 2023

Cell Commun Signal

View full text Add to dashboard Cite

Acute myocardial infarction has long been the leading cause of death in coronary heart disease, which is characterized by irreversible cardiomyocyte death and restricted blood supply. Conventional reperfusion therapy can further aggravate myocardial injury. Stem cell therapy, especially with mesenchymal stem cells (MSCs), has emerged as a promising approach to promote cardiac repair and improve cardiac function. MSCs may induce these effects by secreting exosomes containing therapeutically active RNA, proteins and lipids. Notably, normal cardiac function depends on intracardiac paracrine signaling via exosomes, and exosomes secreted by cardiac cells can partially reflect changes in the heart during disease, so analyzing these vesicles may provide valuable insights into the pathology of myocardial infarction as well as guide the development of new treatments. The present review examines how exosomes produced by MSCs and cardiac cells may influence injury after myocardial infarction and serve as therapies against such injury. Graphical Abstract

show abstract

Bone Marrow Mesenchymal Stem Cell-Derived Exosomal microRNA-29b-3p Promotes Angiogenesis and Ventricular Remodeling in Rats with Myocardial Infarction by Targeting ADAMTS16

Cited by 18 publications

References 31 publications

Mesenchymal stem cell‐derived exosomes in myocardial infarction: Therapeutic potential and application

Mesenchymal stem cell‐derived exosomes in myocardial infarction: Therapeutic potential and application

Mesenchymal stem cell‐derived extracellular vesicles: Recent therapeutics and targeted drug delivery advances

Advances in the study of exosomes derived from mesenchymal stem cells and cardiac cells for the treatment of myocardial infarction

Contact Info

Product

Resources

About